AstraZeneca joins stepped-up antibiotic R&D action with FOB Synthesis deal

AstraZeneca ($AZN) notched an antibiotics research deal with a licensing/option set-up with FOB Synthesis, covering combinations of the two companies' experimental drugs. AstraZeneca plans to test its own beta lactamase inhibitor alongside the smaller company's carbapenem drugs FSI-1671 and FSI-1686. Report